These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30007065)

  • 1. Primary cutaneous CD30
    Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
    Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
    Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
    Madray MM; Greene JF; Butler DF
    Arch Neurol; 2008 Oct; 65(10):1378-9. PubMed ID: 18852356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: Case report and literature review].
    Cesbron E; Monfort JB; Giannesini C; Duriez P; Moguelet P; Senet P; Francès C; Barbaud A; Chasset F
    Ann Dermatol Venereol; 2018; 145(6-7):433-438. PubMed ID: 29673751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplantation primary cutaneous CD30 (Ki-1)-positive large-cell lymphoma.
    Seçkin D; Demirhan B; Oğuz Güleç T; Arikan U; Haberal M
    J Am Acad Dermatol; 2001 Dec; 45(6 Suppl):S197-9. PubMed ID: 11712057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cutaneous anaplastic large cell lymphoma.
    Brown RA; Fernandez-Pol S; Kim J
    J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.
    Masera S; Chiavazza C; Mattioda A; Superti G; Beggiato E; Crosasso P; Broganelli P; Pinessi L; Cavalla P
    Mult Scler; 2014 Oct; 20(12):1666-7. PubMed ID: 24603883
    [No Abstract]   [Full Text] [Related]  

  • 15. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
    Haebich G; Mughal A; Tofazzal N
    Clin Exp Dermatol; 2016 Jun; 41(4):433-4. PubMed ID: 26577239
    [No Abstract]   [Full Text] [Related]  

  • 16. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 17. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
    Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 19. Linfoma anaplásico de células T grandes primario cutáneo CD30+. Serie de nueve casos.
    Ruiz-Arriaga LF; Landgrave-Gómez I; Toussaint-Caire S; Lacy-Niebla RM; Vega-Memije ME
    Gac Med Mex; 2019; 155(2):130-135. PubMed ID: 31056597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.